SCHEMBL775660

SCHEMBL775660

O=S(=O)(Oc1c(F)c(F)c(F)c(F)c1F)C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
TSHR P16473 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CXCR2 P25025 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8264078 0.76 CES2 (0.38) CA1CA2CA9CXCR2
SCHEMBL777316 0.73 HTR1A (0.34) CA1CA2CXCR2
SCHEMBL778173 0.73 CA1 (0.62) CA1CA2CA9
SCHEMBL16140150 0.70 CA1 (0.59) CA1CA2CA9
SCHEMBL1410890 0.70 CA1 (0.41) CA1CA2CA9
SCHEMBL1401591 0.70 CA1 (0.46) CA1CA2CA9
SCHEMBL4333483 0.69 CA2 (0.56) CA1CA2CA9TSHR
SCHEMBL576035 0.69 CA2 (0.50) CA1CA2CA9CXCR2
SCHEMBL585314 0.69 CA1 (0.56) CA1CA2CA9TSHR
SCHEMBL926505 0.69 CA2 (0.41) CA1CA2CA9CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117352668-A Preparation method of pyrophosphate secondary battery positive electrode material with high air stability 深圳珈钠能源科技有限公司 2024-01-05 CN claimed
CN-116365031-A Electrolyte and lithium ion battery 蜂巢能源科技(无锡)有限公司 2023-06-30 CN claimed
US-8530080-B2 Nonaqueous electrolyte solution and lithium secondary battery using same UBE INDUSTRIES, LTD. (JP) 2013-09-10 US claimed
US-20130052541-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME UBE INDUSTRIES, LTD. (JP) 2013-02-28 US claimed
US-20100239919-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME UBE INDUSTRIES, LTD. (JP) 2010-09-23 US claimed
EP-1498978-B1 NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME UBE INDUSTRIES (JP) 2010-09-08 EP claimed
CN-100440607-C Non-aqueous electrolyte solution and lithium secondary battery using the same UBE INDUSTRIES (JP) 2008-12-03 CN claimed
US-7297442-B2 Nonaqueous electrolytic solution and lithium secondary battery employing the same UBE INDUSTRIES, LTD. (JP) 2007-11-20 US claimed
US-20050255384-A1 Nonaqueous electrolytic solution and lithium secondary battery employing the same UBE INDUSTRIES, LTD (JP) 2005-11-17 US claimed
CN-1653642-A Non-aqueous electrolyte solution and lithium secondary battery using the same UBE INDUSTRIES (JP) 2005-08-10 CN claimed
EP-1498978-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME Ube Industries, Ltd. (JP) 2005-01-19 EP claimed
US-20260103707-A1 NOVEL COMPOUND AND APPLICATION THEREOF KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) 2026-04-16 US disclosed
US-20260103708-A1 NOVEL COMPOUND AND APPLICATION THEREOF KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) 2026-04-16 US disclosed
EP-4681773-A9 NOVEL COMPOUND AND APPLICATION THEREOF Kylonova (Xiamen) Biopharma Co., Ltd. (CN) 2026-03-18 EP disclosed
EP-4681773-A2 NOVEL COMPOUND AND APPLICATION THEREOF Kylonova (Xiamen) Biopharma Co., Ltd. (CN) 2026-01-21 EP disclosed
US-20070054185-A1 Performance such as cycle characteristics, electric capacity, and storage characteristics UBE INDUSTRIES, LTD. (JP) 2007-03-08 US disclosed
EP-1672729-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME Ube Industries, Ltd. (JP) 2006-06-21 EP disclosed
US-20050255384-A1 Nonaqueous electrolytic solution and lithium secondary battery employing the same UBE INDUSTRIES, LTD (JP) 2005-11-17 US disclosed
CN-1653642-A Non-aqueous electrolyte solution and lithium secondary battery using the same UBE INDUSTRIES (JP) 2005-08-10 CN disclosed
EP-1498978-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME Ube Industries, Ltd. (JP) 2005-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103708-A1 NOVEL COMPOUND AND APPLICATION THEREOF NSUN2, HAVCR2, GALNT2 CA1 4257/4885CA2 4738/4885CA9 3255/4885
US-20260103707-A1 NOVEL COMPOUND AND APPLICATION THEREOF GALNT10, FUT5, FUT6 CA1 3978/4885CA2 4665/4885CA9 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.